Lv11
44 积分 2023-09-26 加入
PD‐1‐Cis IL‐2R Agonism Determines the Predicted Pharmacological Dose Range for the Immunocytokine Eciskafusp Alfa (PD1‐IL2v)
3小时前
已完结
A systematic review of allometric scaling exponents for IgG mAbs
2个月前
已完结
Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology
2个月前
已完结
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice
3个月前
已完结
American Society for Clinical Pharmacology and Therapeutics
3个月前
已完结
A Mechanistic Physiologically‐Based Pharmacokinetic Platform Model to Guide Adult and Pediatric Intravenous and Subcutaneous Dosing for Bispecific T Cell Engagers
3个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
3个月前
已完结
The most frequent HLA alleles around the world: A fundamental synopsis
4个月前
已关闭
Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules – A survey of industry 2008–2019
7个月前
已完结
Regulatory Forum Opinion Piece*
7个月前
已完结
皖公网安备34019202002308
